New fibromyalgia drug AXS-14 enters final testing phase
NCT ID NCT07398417
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tests whether AXS-14 (esreboxetine) can help manage fibromyalgia symptoms like pain and fatigue. About 620 adults with fibromyalgia will take the drug or a placebo daily. The study uses a 'randomized withdrawal' design to see how long the drug's effects last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AXS-14 (esreboxetine) tablets taken once daily
What this could lead to
If successful, AXS-14 could offer a new daily medication option to help manage fibromyalgia pain and other symptoms.
What could go wrong
This is a Phase 3 trial, but it's a withdrawal study—meaning it tests if stopping the drug leads to symptom return. It may not work for everyone, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROMYALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Site
RECRUITINGLittle Rock, Arkansas, 72211, United States
-
Clinical Research Site
RECRUITINGSanta Ana, California, 92705, United States
-
Clinical Research Site
RECRUITINGCromwell, Connecticut, 06416, United States
-
Clinical Research Site
RECRUITINGJacksonville, Florida, 32256, United States
-
Clinical Research Site
RECRUITINGOrlando, Florida, 32801, United States
-
Clinical Research Site
RECRUITINGTampa, Florida, 33634, United States
-
Clinical Research Site
RECRUITINGAtlanta, Georgia, 30329, United States
-
Clinical Research Site
RECRUITINGOverland Park, Kansas, 66209, United States
-
Clinical Research Site
RECRUITINGLouisville, Kentucky, 40205, United States
-
Clinical Research Site
RECRUITINGPrairieville, Louisiana, 70769, United States
-
Clinical Research Site
RECRUITINGSpringfield, Missouri, 65807, United States
-
Clinical Research Site
RECRUITINGTown and Country, Missouri, 63017, United States
-
Clinical Research Site
RECRUITINGTulsa, Oklahoma, 74133, United States
-
Clinical Research Site
RECRUITINGCharleston, South Carolina, 29407, United States
-
Clinical Research Site
RECRUITINGMemphis, Tennessee, 38119, United States
-
Clinical Research Site
RECRUITINGProsper, Texas, 75078, United States